Literature DB >> 29543134

Inspiratory muscle training reduces diaphragm activation and dyspnea during exercise in COPD.

Daniel Langer1,2, Casey Ciavaglia1, Azmy Faisal1,3, Katherine A Webb1, J Alberto Neder1, Rik Gosselink2, Sauwaluk Dacha2,4, Marko Topalovic5, Anna Ivanova6, Denis E O'Donnell1.   

Abstract

Among patients with chronic obstructive pulmonary disease (COPD), those with the lowest maximal inspiratory pressures experience greater breathing discomfort (dyspnea) during exercise. In such individuals, inspiratory muscle training (IMT) may be associated with improvement of dyspnea, but the mechanisms for this are poorly understood. Therefore, we aimed to identify physiological mechanisms of improvement in dyspnea and exercise endurance following inspiratory muscle training (IMT) in patients with COPD and low maximal inspiratory pressure (Pimax). The effects of 8 wk of controlled IMT on respiratory muscle function, dyspnea, respiratory mechanics, and diaphragm electromyography (EMGdi) during constant work rate cycle exercise were evaluated in patients with activity-related dyspnea (baseline dyspnea index <9). Subjects were randomized to either IMT or a sham training control group ( n = 10 each). Twenty subjects (FEV1 = 47 ± 19% predicted; Pimax  = -59 ± 14 cmH2O; cycle ergometer peak work rate = 47 ± 21% predicted) completed the study; groups had comparable baseline lung function, respiratory muscle strength, activity-related dyspnea, and exercise capacity. IMT, compared with control, was associated with greater increases in inspiratory muscle strength and endurance, with attendant improvements in exertional dyspnea and exercise endurance time (all P < 0.05). After IMT, EMGdi expressed relative to its maximum (EMGdi/EMGdimax) decreased ( P < 0.05) with no significant change in ventilation, tidal inspiratory pressures, breathing pattern, or operating lung volumes during exercise. In conclusion, IMT improved inspiratory muscle strength and endurance in mechanically compromised patients with COPD and low Pimax. The attendant reduction in EMGdi/EMGdimax helped explain the decrease in perceived respiratory discomfort despite sustained high ventilation and intrinsic mechanical loading over a longer exercise duration. NEW &amp; NOTEWORTHY In patients with COPD and low maximal inspiratory pressures, inspiratory muscle training (IMT) may be associated with improvement of dyspnea, but the mechanisms for this are poorly understood. This study showed that 8 wk of home-based, partially supervised IMT improved respiratory muscle strength and endurance, dyspnea, and exercise endurance. Dyspnea relief occurred in conjunction with a reduced activation of the diaphragm relative to maximum in the absence of significant changes in ventilation, breathing pattern, and operating lung volumes.

Entities:  

Keywords:  chronic obstructive pulmonary disease; diaphragm; dyspnea; electromyogram; exercise; inspiratory muscle strength; respiratory mechanics

Mesh:

Year:  2018        PMID: 29543134     DOI: 10.1152/japplphysiol.01078.2017

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  19 in total

1.  New method for evaluating maximal respiratory pressures: Concurrent validity, test-retest, and inter-rater reliability.

Authors:  Bruna M F Silveira; Manoel C B Pereira; Daniella R Cardoso; Giane A Ribeiro-Samora; Henrique R Martins; Verônica F Parreira
Journal:  Braz J Phys Ther       Date:  2021-05-14       Impact factor: 3.377

2.  Effect of high quality nursing and respiratory training on pulmonary function and quality of life in patients with chronic obstructive pulmonary disease.

Authors:  Qiubo Zhang; Sufang Liu; Gang Gu; Lingbo Wu; Zimeng Zhu; Yuhong Mao; Fen Zhang
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

3.  Metabolomic profiling of anaerobic and aerobic energy metabolic pathways in chronic obstructive pulmonary disease.

Authors:  Mingshan Xue; Yifeng Zeng; Runpei Lin; Hui-Qi Qu; Teng Zhang; Xiaohua Douglas Zhang; Yueting Liang; Yingjie Zhen; Hao Chen; Zhifeng Huang; Haisheng Hu; Peiyan Zheng; Hakon Hakonarson; Luqian Zhou; Baoqing Sun
Journal:  Exp Biol Med (Maywood)       Date:  2021-05-06

Review 4.  Activity-related dyspnea in chronic obstructive pulmonary disease: physical and psychological consequences, unmet needs, and future directions.

Authors:  Nicola A Hanania; Denis E O'Donnell
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-05-24

5.  Assessing the effects of inspiratory muscle training in a patient with unilateral diaphragm dysfunction.

Authors:  Mayra Caleffi Pereira; Sauwaluk Dacha; Dries Testelmans; Rik Gosselink; Daniel Langer
Journal:  Breathe (Sheff)       Date:  2019-06

Review 6.  Dyspnea in COPD: New Mechanistic Insights and Management Implications.

Authors:  Denis E O'Donnell; Kathryn M Milne; Matthew D James; Juan Pablo de Torres; J Alberto Neder
Journal:  Adv Ther       Date:  2019-10-30       Impact factor: 3.845

Review 7.  Effect of muscle training on dyspnea in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized controlled trials.

Authors:  Fang Zhang; Yaping Zhong; Zheng Qin; Xiaomeng Li; Wei Wang
Journal:  Medicine (Baltimore)       Date:  2021-03-05       Impact factor: 1.817

8.  Time to Move Beyond a "One-Size Fits All" Approach to Inspiratory Muscle Training.

Authors:  Ren-Jay Shei; Hunter L Paris; Abigail S Sogard; Timothy D Mickleborough
Journal:  Front Physiol       Date:  2022-01-10       Impact factor: 4.566

9.  Interventions for promoting physical activity in people with chronic obstructive pulmonary disease (COPD).

Authors:  Angela T Burge; Narelle S Cox; Michael J Abramson; Anne E Holland
Journal:  Cochrane Database Syst Rev       Date:  2020-04-16

10.  Effect of Abdominal Binding on Diaphragmatic Neuromuscular Efficiency, Exertional Breathlessness, and Exercise Endurance in Chronic Obstructive Pulmonary Disease.

Authors:  Sara J Abdallah; Benjamin M Smith; Courtney Wilkinson-Maitland; Pei Zhi Li; Jean Bourbeau; Dennis Jensen
Journal:  Front Physiol       Date:  2018-11-14       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.